AbbVie gets key FDA OK for migraine drug Qulipta

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.

AbbVie sees bigger role for Qulipta in migraine prevention

AbbVie's Qulipta has become the first oral drug in the CGRP inhibitor class to show efficacy in chronic migraine prevention in a pivotal trial, setting it up for a role in a category curren

NICE backs Lilly’s Emgality for migraine, adding pressure on...

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve th

CHMP turns down Lilly’s Emgality for cluster headache

Blow to Novartis as NICE rejects migraine drug Aimovig again

Breakthrough migraine prevention treatment approved in Europ...

Novartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine prevention jab available for adult patients in Euro